Conferences

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

February 9th 2022

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

Challenges of Cell Therapy in Solid Tumors: Julian Molina, MD, PhD

January 25th 2022

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

January 17th 2022

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.

Improving Outcomes in Solid Tumors With Personalized Cell Therapies

January 15th 2022

Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.

Improving Cancer Survival With Immunotherapy: Julian Molina, MD, PhD

January 8th 2022

The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.

Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD

December 12th 2021

The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.

Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD

December 9th 2021

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.

Improving Personalized Cell Therapies for Solid Tumors

December 9th 2021

Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.

Identifying Future Patients for Tmod Cell Therapy in BASECAMP-1: Julian Molina, MD, PhD

December 3rd 2021

The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.

CRISPR/Cas9-Edited CAR and NK Cell Therapies Show Preclinical Efficacy

November 28th 2021

CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.